<DOC>
	<DOCNO>NCT01046214</DOCNO>
	<brief_summary>The objective study evaluate comparative bioavailability bupropion hydrochloride 300 mg extend release tablet ( Teva Pharmaceuticals USA ) Wellbutrin XL® 300 mg extend release tablet ( Biovail Pharmaceuticals , Inc. ) steady-state patient fasting condition .</brief_summary>
	<brief_title>Bupropion Hydrochloride 300 mg Extended Release Tablets Under Fasting Conditions</brief_title>
	<detailed_description />
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Bupropion</mesh_term>
	<criteria>Male female patient , 25 year age old Diagnosis depressive disorder per DSM IV criterion ( except bipolar depression major depressive disorder psychotic feature ) . Note : Both patient treat bupropion antidepressant permit study . Patients must complain suffer adverse event and/or lack effect switch Wellbutrin XL® 300 mg Budeprion XL™ 300 mg. BMI ( kg/m2 ) Greater equal 19 less equal 34 . No clinically significant abnormal laboratory value No clinically significant finding 12lead electrocardiogram ( ECG ) No clinically significant finding vital sign measurement . Be informed nature study give write consent prior receive study procedure . Exclusion Criteria Carcinoma within last 5 year . Note : Patients basal squamous cell carcinoma may permit study case case basis . A history epilepsy risk seizure . A previous current diagnosis bipolar depression . A current diagnosis major depressive episode psychotic feature . Note : Subjects previous diagnosis major depressive episode psychotic feature may include investigator 's discretion . A previous current diagnosis eat disorder ( e.g . bulimia , anorexia nervosa ) . A lifetime history schizophrenia schizoaffective disorder . Significant disease ( ) clinically significant finding ( ) physical examination determine investigator pose health concern patient study . Presence clinically significant gastrointestinal disease and/or surgery ( e.g . gastric bypass surgery ) history malabsorption within last year . Known history presence allergic sensitivity bupropion and/or drug substance similar activity . Expected change use permitted concomitant medication continue throughout study . Undergoing abrupt discontinuation sedative ( include benzodiazepine ) . Use monoamine oxidase inhibitor ( MAOI ) within 2 week prior study admission . Taking medication interact CYP2B6 within 30 day prior Day 1 dosing . Taking levodopa , amantadine , drug low seizure threshold ( e.g . theophylline , systemic steroid , antipsychotic ) , and/or nicotine replacement therapy . History alcohol drugdependence DSM IV criterion within 6 month prior study admission . Positive test result : HIV Hepatitis B surface antigen Hepatitis C antibody Urine drug abuse ( i.e . marijuana , amphetamine , barbiturate , cocaine , opiates , methadone , phencyclidine ) Note : positive test result ( ) benzodiazepine ( ) must assess investigator determine whether patient exclude study . Serum hCG consistent pregnancy ( female ) . On special diet within 30 day prior study admission ( e.g . liquid , protein , raw food diet ) . Difficulty fast consume standard meal . Participated another clinical trial receive investigational product within 45 day prior Day 1 drug administration . Donation loss whole blood : Less equal 499 mL within 30 day prior dose Greater equal 500 mL within 56 day prior dose Note : blood take routine medical evaluation total less 50 mL permit . Females discontinue use : implant , intrauterine , inject hormonal contraceptive within 6 month prior Day 1 drug administration , OR oral , intravaginal , patch hormonal contraceptive within 1 month prior Day 1 drug administration Females start take : implant intrauterine hormonal contraceptive le 6 month prior Day 1 drug administration , OR oral , intravaginal , patch , inject hormonal contraceptive le 3 month prior Day 1 drug administration . Females pregnant , lactating , likely become pregnant study . Have newly apply tattoo body pierce within 30 day prior study admission . Does tolerate venipuncture . Unable unwilling provide inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>25 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>